柔光在治疗子宫内膜异位症中的作用:疼痛症状以外的影响。

IF 3.1 Q1 OBSTETRICS & GYNECOLOGY Therapeutic advances in reproductive health Pub Date : 2020-12-01 eCollection Date: 2020-01-01 DOI:10.1177/2633494120964517
David F Archer, Ahmed M Soliman, Sanjay K Agarwal, Hugh S Taylor
{"title":"柔光在治疗子宫内膜异位症中的作用:疼痛症状以外的影响。","authors":"David F Archer, Ahmed M Soliman, Sanjay K Agarwal, Hugh S Taylor","doi":"10.1177/2633494120964517","DOIUrl":null,"url":null,"abstract":"<p><p>While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain associated with endometriosis. However, the benefits of elagolix extend beyond reducing pain symptoms. This article reviews the non-pain systemic manifestations associated with endometriosis and summarizes the beneficial effects of elagolix on non-pain outcomes. This includes improvements in quality of life, reductions in fatigue and improvements in workplace and household productivity. These results indicate that elagolix provides non-pain benefits in women with endometriosis and improves outcomes that are clinically meaningful to patients.</p>","PeriodicalId":75219,"journal":{"name":"Therapeutic advances in reproductive health","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2633494120964517","citationCount":"7","resultStr":"{\"title\":\"Elagolix in the treatment of endometriosis: impact beyond pain symptoms.\",\"authors\":\"David F Archer, Ahmed M Soliman, Sanjay K Agarwal, Hugh S Taylor\",\"doi\":\"10.1177/2633494120964517\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain associated with endometriosis. However, the benefits of elagolix extend beyond reducing pain symptoms. This article reviews the non-pain systemic manifestations associated with endometriosis and summarizes the beneficial effects of elagolix on non-pain outcomes. This includes improvements in quality of life, reductions in fatigue and improvements in workplace and household productivity. These results indicate that elagolix provides non-pain benefits in women with endometriosis and improves outcomes that are clinically meaningful to patients.</p>\",\"PeriodicalId\":75219,\"journal\":{\"name\":\"Therapeutic advances in reproductive health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/2633494120964517\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic advances in reproductive health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2633494120964517\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic advances in reproductive health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2633494120964517","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 7

摘要

虽然与子宫内膜异位症相关的最常见症状是盆腔疼痛,但该疾病的全身性表现以及伴随的不良心理、情感、社会、家庭、性、教育和工作场所影响越来越被认识到。Elagolix是一种口服促性腺激素释放激素受体拮抗剂,被批准用于治疗与子宫内膜异位症相关的中度至重度疼痛。然而,elagolix的好处不仅仅是减轻疼痛症状。本文综述了与子宫内膜异位症相关的非疼痛性全身性表现,并总结了美乐柔对非疼痛结局的有益作用。这包括提高生活质量,减少疲劳,提高工作场所和家庭生产力。这些结果表明,elagolix为患有子宫内膜异位症的女性提供了无痛的益处,并改善了对患者有临床意义的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Elagolix in the treatment of endometriosis: impact beyond pain symptoms.

While the most common symptom associated with endometriosis is pelvic pain, the systemic manifestations of the disease and the accompanying adverse psychological, emotional, social, familial, sexual, educational and workplace effects are increasingly recognized. Elagolix is an oral gonadotropin-releasing hormone receptor antagonist that is approved for the management of moderate to severe pain associated with endometriosis. However, the benefits of elagolix extend beyond reducing pain symptoms. This article reviews the non-pain systemic manifestations associated with endometriosis and summarizes the beneficial effects of elagolix on non-pain outcomes. This includes improvements in quality of life, reductions in fatigue and improvements in workplace and household productivity. These results indicate that elagolix provides non-pain benefits in women with endometriosis and improves outcomes that are clinically meaningful to patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
7 weeks
期刊最新文献
Comparing visual estimation and hematocrit change in the assessment of blood loss among women undergoing cesarean delivery in a tertiary facility in northern Uganda. Exploring challenges to the uptake of sexual and reproductive health services among lesbian and bisexual women in Bulawayo, Zimbabwe: a qualitative enquiry. The role of artificial intelligence in transforming maternity services in Africa: prospects and challenges. Comparison of urine protein-creatinine ratio and urine dipstick test for significant proteinuria in preeclamptic women. Reproductive and oncologic outcomes in young women with uterine sarcoma undergoing fertility-sparing treatment: a systematic review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1